$51.40▼ 3.71 (6.73%)
Real-time prices · US MarketsHealthy balance sheet and financial position.
weak profitability metrics drag quality score.
Quality
4.4
Health
5
Growth
5
Valuation
5
Sentiment
5
Analyst Target
—
Price Chart
Latest News
- Cathie Wood Loads Up On TEM, ILMN And Biotech Stocks — But Pares Stake In This Pharma Giant That Had A Blowout Q3
- Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.
- Cathie Wood-Led Ark Invest Sells AMD, SPCX, GOOG Stocks — But Loads Up On CMPS, NTLA, CRSP And Other Healthcare Firms
Fundamentals
Trailing P/E
—
price-to-earnings
Forward P/E
—
next 12 months est.
Market Cap
—
market capitalization
Div Yield
—
dividend yield
Profit Margin
—
net profit margin
Gross Margin
—
revenue minus COGS
ROE
—
return on equity
Beta
—
vs S&P 500
52-Week Range
$25 — $59
annual min — max
Frequently Asked Questions
What do analysts say about ARK Genomic Revolution ETF right now?
ARK Genomic Revolution ETF's Q·Score is 4.8/10 (Bearish), reflecting its current fundamentals, analyst data, and valuation metrics. Healthy balance sheet and financial position. Key area to monitor: weak profitability metrics drag quality score. This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.
Is ARKG overvalued or undervalued?
ARK Genomic Revolution ETF (ARKG) scores in line with sector averages on valuation metrics.